Carmenta Bio

Curated by Signal

Diagnostics for women's health

Overview

Carmenta Bioscience, a Stanford spin-out, developed diagnostics for women's health. Its platform combined proprietary computational algorithms with protein sera measurements for maternal diagnostics. Its flagship product was a diagnostic test for preeclampsia in both symptomatic and asymptomatic expectant mothers. In April 2015, Carmenta was acquired by Progenity.

Key facts

Founded: 2012
Headquarters: Palo Alto, United States
Stage: Sign up to view
Industry: Life Sciences Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

GlucoTech
Developer of connected blood glucose monitoring device
Life Sciences TechnologyIrvine, United States
AIQ Solutions
Provider of intelligent solutions for precision medicine
Life Sciences TechnologyMadison, United States
MMUSA
Online e-commerce platform for fitness supplements
Life Sciences TechnologyCarson City, United States

About Carmenta Bio

What does Carmenta Bio do?

Carmenta Bioscience, a Stanford spin-out, developed diagnostics for women's health.

Where is Carmenta Bio headquartered?

Carmenta Bio is headquartered in Palo Alto, United States.

When was Carmenta Bio founded?

Carmenta Bio was founded in 2012.

Which sector is Carmenta Bio in?

Carmenta Bio operates in Life Sciences Technology.

Who are Carmenta Bio's competitors?

Companies similar to Carmenta Bio include GlucoTech, AIQ Solutions, and MMUSA.